Outcome of 6 months MBMDT in MB patients in Bangladesh- preliminary results.

  title={Outcome of 6 months MBMDT in MB patients in Bangladesh- preliminary results.},
  author={Cynthia Ruth Butlin and David Pahan and Aung Kya Jai Maug and Stephen G Withington and Peter Nicholls and Khorshed Alam and M A Hamid Salim},
  journal={Leprosy review},
  volume={87 2},
Introduction Duration of leprosy treatment remains long and difficult to complete in resource poor areas. Studies suggest that shortening duration of therapy for MB patients to 6 months may be possible. Methods New MB patients in 2005 in two NGO projects in Bangladesh were treated with 6 months WHO MB MDT and the rate of relapse and fall in BI on slit skin smear during follow up to date were compared with a control group treated for 12 months the previous year. Results 1612 patients were… 

Figures and Tables from this paper

Uniform multidrug therapy for leprosy patients in Brazil (U-MDT/CT-BR): Results of an open label, randomized and controlled clinical trial, among multibacillary patients

The hypothesis that UMDT is an acceptable option to be adopted in endemic countries to treat leprosy patients in the field worldwide is supported.

Uniform multidrug therapy for leprosy – time for a rethink?

Important considerations were that very little evidence was available at that time concerning the efficacy of 12 months treatment, or about the level of rifampicin resistance that could potentially be developing undetected in leprosy patients on MDT, and it would be unwise to attempt further shortening of the regimen.

Clinical trial for uniform multidrug therapy for leprosy patients in Brazil (U-MDT/CT-BR): adverse effects approach*

Adverse effects do not represent a constraint to recommend the six-month uniform regimen of treatment for all leprosy patients, and anemia was greater in patients from the R-MDT/MB group, therefore adverse effects did not represent an constraint.

Leprosy: current situation, clinical and laboratory aspects, treatment history and perspective of the uniform multidrug therapy for all patients*

The drug acceptability, reduction in treatment duration and the most recent proposal of a single therapeutic regimen, with a fixed six months duration, for all clinical presentations, regardless of their classification are highlighted.

Treatment and Evaluation Advances in Leprosy Neuropathy

A variety of established as well as new methods for the early diagnosis and assessment of leprosy neuropathy are reviewed and a candidate vaccine has shown apparent benefit in preventing nerve injury in the armadillo model.

Three drugs are unnecessary for treating paucibacillary leprosy—A critique of the WHO guidelines

The evidence used to make these recommendations to treat leprosy patients with three antibacterial drugs is found lacking and certain recommendations, although agreed upon unanimously by the GDG, are based on insufficient evidence.

Guidelines for the Diagnosis, Treatment and Prevention of Leprosy

The GLP is particularly grateful to the persons affected by leprosy who participated in focus group discussions in Colombia, Ghana, India and Nepal on diagnosis, treatment and contact screening.

Eff ec! vity of Uniform Mul! drug Therapy on the Success of Paucibacillary and Mul! bacillary Leprosy Treatment

There has not been a report on the use of U-MDT as part of a leprosy control program in any country, except as clinical trials or for research purposes, today.

Safer and newer antimicrobial drugs for leprosy – time to test monthly ROM in an adequately powered randomised trial?

Diana N. J. Lockwooda,b, Gerson O. Pennac, Saba Lambertd,e, Vivek Vasudev Paif & Stephen L. Walkerg,h aEmeritus Professor of Tropical Medicine, Faculty of Infectious and Tropical Diseases, London

ISSN: 2595-6825

It can be concluded that bulk- Fill and conventional resin composites tested present similar properties and shorter time required for the use associated with simplified operative technique are considered clinical advantages of bulk-fill composites.



The relapse rate in MB leprosy patients treated with 2-years of WHO-MDT is not low.

A group of multibacillary patients is clearly at high risk for relapse following 2-yr WHO-MDT, and might well benefit from an alternative antimicrobial regimen from the outset, as well as upon relapse.

Treatment with corticosteroids of long-standing nerve function impairment in leprosy: a randomized controlled trial (TRIPOD 3).

The trial confirms current practice not to treat long-standing NFI with prednisolone, and underscores the need to keep patients under regular surveillance during MDT, and, where possible, after completion of MDT.

Relapse in leprosy.

Clinicians may need to use their judgement to modify the standard WHO treatment regimens according to the scenario in each patient, and factors that should be considered are the type of leprosy (PB or MB), previous treatment and drug resistance.

Six years' follow‐up of multibacillary leprosy patients treated with uniform multi‐drug therapy in China

This study was conducted to evaluate the effectiveness of uniform multi‐drug therapy (UMDT) in patients with multibacillary (MB) leprosy.

leprosy patients in Brasil: reactions frequency in Multi-bacillary patients

  • Lepr Rev,
  • 2012

leprosy patients in Brasil: decrease in bacteriological index

  • Lepr Rev,
  • 2014

Bacteriological response and leprosy reaction amongst MB leprosy patients treated with uniform MDT in China

  • Lepr Rev
  • 2012

Primary results of clinical trial of uniform Multi - drug therapy for leprosy patients in Brasil : reactions frequency in Multi - bacillary patients

  • Lepr Rev
  • 2012

treated with uniform MDT in China

  • Lepr Rev,
  • 2012